Summary
This analysis of atezolizumab efficacy in platinum-treated urothelial carcinoma examines how prior treatment history influences clinical outcomes. The study stratifies outcomes by number of previous therapy regimens, as suggested by the title, to characterise treatment response across patient populations with varying prior exposure to chemotherapy. Published in European Urology in 2017, it contributes to understanding checkpoint inhibitor performance in this cancer indication.
UK applicability
Findings on immunotherapy efficacy in urothelial carcinoma are applicable to UK oncology practice and NHS treatment guidelines, though geographic variation in patient populations and healthcare systems should be considered when translating outcomes.
Key measures
Overall response rate, overall survival, progression-free survival, adverse event frequency and severity by prior regimen count
Outcomes reported
The study examined efficacy and safety outcomes of atezolizumab in patients with locally advanced or metastatic urothelial carcinoma stratified by prior treatment regimen history. Response rates, overall survival, and adverse events were assessed across patient subgroups with differing numbers of prior chemotherapy lines.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.